This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Solvent choice depends on peptide polarity and intended use. Many peptides dissolve in water or buffered aqueous solutions, while hydrophobic sequences may need a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before aqueous dilution. The solvent should match the downstream analytical method and not interfere with detection. Gentle mixing or brief sonication can help, but vigorous agitation may promote foaming or aggregation. Complete dissolution is judged by a clear liquid free of visible particles, though some turbidity can persist.
Reconstitution concentration is chosen from the mass of peptide and the volume of solvent added. Researchers often prepare a concentrated stock and then divide it into single-use aliquots to reduce freeze-thaw cycling. The actual peptide content may differ from label mass because of counterions, water, or impurities. For that reason, quantitative work may require independent measurement such as amino acid analysis or ultraviolet absorbance. Records of solvent, volume, date, and lot help trace later observations.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
The choice of solvent depends on the peptide's sequence, charge, and solubility profile. Water is common for hydrophilic peptides, while aqueous mixtures containing acetonitrile, methanol, or a small amount of acid may be needed for hydrophobic or basic sequences. Adding the liquid to the powder, rather than the reverse, can reduce clumping and improve wetting. Gentle mixing or brief vortexing may help, but vigorous agitation can create foam and shear sensitive structures. Complete dissolution is judged by a clear solution with no visible particles.
| Property | Value | Notes |
|---|---|---|
| Appearance (lyophilized) | White to off-white powder or cake | Depends on peptide sequence, counterion, and manufacturing process |
| Appearance (reconstituted) | Clear to slightly hazy solution | Visible particles may indicate incomplete dissolution or aggregation |
| Solubility class | Aqueous or organic-dependent | Hydrophilic peptides often dissolve in water; hydrophobic peptides may require acetonitrile or dimethyl sulfoxide |
| Typical storage temperature (lyophilized) | -20 °C or lower | Desiccated, protected from light, and allowed to equilibrate before opening |
| Typical analytical method | Reverse-phase HPLC or LC-MS | Used to confirm identity, purity, and concentration after dissolution |
== Production == TMU is obtained by the reaction of dimethylamine with phosgene in aqueous sodium hydroxide in a 2:1 ratio. A similar method combines dimethylcarbamoyl chloride with excess dimethylamine. This reaction is highly exothermic. The removal of the resulting dimethylamine hydrochloride requires some effort.
Additionally, patients have not substituted other drugs as a method of overdose. The decision to withdraw co-proxamol has met with some controversy; it has been brought up in the House of Commons on two occasions, 13 July 2005 and on 17 January 2007. Patients have found alternatives to co-proxamol either too strong, too weak, or with intolerable side effects. During the House of Commons debates, it is quoted that originally some 1,700,000 patients in the UK were prescribed co-proxamol. Following the phased withdrawal, this has eventually been reduced to 70,000. However, this apparently is the residual pool of patients who cannot find alternate analgesia to co-proxamol. The safety net of prescribing co-proxamol after license withdrawal from 31 December 2007, on a "named patient" basis where doctors agree a clinical need exists, has been rejected by most UK doctors because the wording that "responsibility will fall on the prescriber" is unacceptable to most doctors. Some patients intend to take the case to the European Court of Human Rights. However, the European Medicines Agency has recently backed the agency's decision, and recommended in June 2009 that propoxyphene preparations be withdrawn across the European Union. On 28 March 2017, NHS Clinical Commissioners announced that co-proxamol will be no longer available under NHS England as part of £400m of spending cuts for prescriptions that are believed to have little or no clinical value.
European ancestry being dominant according to all autosomal studies undertaken covering the population, accounting for between 60% and 65% of the average genetic makeup of the Brazilian population. African ancestry among the Brazilians is estimated at 20% to 25% of the average genetic makeup Indigenous ancestry is significant and present in all regions of Brazil, accounting for around 15% to 20% of the average genetic ancestry of Brazilians. From the 19th century, Brazil opened its borders to immigration. About five million people from over 60 countries migrated to Brazil between 1808 and 1972, most of them of Portuguese, Italian, Spanish, German, English, Ukrainian, Polish, Jewish, African, Armenian, Russian, Chinese, Japanese, Korean and Arab origin. Brazil has the second-largest Jewish community in Latin America after Argentina making up 0.06% of its population. Outside of the Arab world, Brazil also has the largest population of Arab ancestry in the world, with 15–20 million people. According to Brazil's Ministry of Foreign Affairs, Brazil is home to a Lebanese diaspora of 7-10 million, surpassing the population of Lebanese individuals residing in Lebanon. Brazilian society is more markedly divided by social class lines, although a high income disparity is found between race groups, so racism and classism often overlap.
Sources: en.wikipedia.org
== Elongation == Elongation of the polypeptide chain involves addition of amino acids to the carboxyl end of the growing chain. The growing protein exits the ribosome through the polypeptide exit tunnel in the large subunit. Elongation starts when the fMet-tRNA enters the P site, causing a conformational change which opens the A site for the new aminoacyl-tRNA to bind. This binding is facilitated by elongation factor-Tu (EF-Tu), a small GTPase. For fast and accurate recognition of the appropriate tRNA, the ribosome utilizes large conformational changes (conformational proofreading). Now the P site contains the beginning of the peptide chain of the protein to be encoded and the A site has the next amino acid to be added to the peptide chain. The growing polypeptide connected to the tRNA in the P site is detached from the tRNA in the P site and a peptide bond is formed between the last amino acids of the polypeptide and the amino acid still attached to the tRNA in the A site. This process, known as peptide bond formation, is catalyzed by a ribozyme (the 23S ribosomal RNA in the 50S ribosomal subunit). Now, the A site has the newly formed peptide, while the P site has an uncharged tRNA (tRNA with no amino acids). The newly formed peptide in the A site tRNA is known as dipeptide and the whole assembly is called dipeptidyl-tRNA. The tRNA in the P site minus the amino acid is known to be deacylated.
== Etymologies == The company's first outlets were in Dallas, named "Tote'm Stores" because customers "toted" away their purchases. Some stores featured "native" totem poles in front of the store. In 1946, the chain's name was changed from "Tote'm" to "7-Eleven" to reflect the company's new, extended hours, 7:00 a.m. to 11:00 p.m., seven days per week. In July 1999, the corporate name of the U.S. company was changed from "The Southland Corporation" to "7-Eleven Inc." Since 1968, 7-Eleven's logos have included a lowercase n. The first wife of John P. Thompson Sr., the company's president during the 1960s, thought the all-capitals version seemed a little aggressive. She suggested the change "to make the logo look more graceful".
=== Colour variations === Breeders have created different colour variations, principally varying proportions of red and blue colouring. The powder blue variant is almost entirely bright blue. The reddest variety (flame red) can be confused with the red variety of honey gouramis (Trichogaster chuna). One of the most common color morphs is the turquoise / neon blue, featuring stripes of dark red and bright blue.
In June 2020, Lilly announced that, in collaboration with Vancouver-based AbCellera, it had begun the world's first study of a potential monoclonal antibody treatment for treatment of COVID-19, with a Phase 1 trial of LY-CoV555. By August 2020, the challenging aspects of running a clinical trial in a long-term care facility during a pandemic prompted Lilly to create the first of many customized recreational vehicles into mobile research units (MRU) to meet people where they were and support mobile labs and clinical trial material preparation. A trailer truck could escort the MRU with supplies to create an on-site infusion clinic. Lilly deployed the mobile research unit fleet in response to outbreaks of the virus at long-term care facilities across the US. In September 2020, Amgen partnered with Lilly to manufacture COVID-19 antibody therapies. In October 2020, Lilly announced that its cocktail was effective and that it had filed with the FDA for an emergency use authorization (EUA). The same day, Regeneron Pharmaceuticals also filed for an EUA for its own monoclonal antibody treatment. The same month, Lilly announced it would acquire Disarm Therapeutics and its experimental treatments for axonal degeneration, via SARM1 inhibitors, for $135 million plus up to another $1.225 billion based on regulatory and commercial milestones.
Sources: en.wikipedia.org
==== Ghana ==== In 2018, Zipline signed a contract with the government of Ghana to make up to 600 deliveries a day for four years at the cost of about $12.5 million. In April 2019, Ghana's president Nana Akufo-Addo announced the opening of the first distribution center in Ghana. Vice President Mahamudu Bawumia launched the first Zipline drone to Tafo Hospital on April 24, 2019. This first delivery contained a resupply shipment of yellow fever vaccines to prevent stock-out. In 2021, the government of Ghana expanded its contract with Zipline to add four additional distribution centers, bringing the total number of contracted distribution centers in the country to eight. Zipline presently operates six distribution centers in Ghana, serving over 2,300 health facilities. When the network is complete, Zipline will be able to serve about 85 percent of the population directly and the remainder indirectly, reaching over 3,200 health facilities in every region of the country. In March 2022, Zipline announced that the company had delivered over one million doses of the COVID-19 vaccine by drone in Ghana over the prior year. An independent study of Zipline's impact on the health system in Ghana found that Zipline's drone delivery service shortened vaccine stock-outs by 60 percent, decreased inventory-driven missed vaccination opportunities by 42 percent, decreased days facilities were without critical medical supplies by 21 percent, and increased the types of medicines and supplies stocked at health facilities by 10 percent.
It appears that this gene loss has happened several times independently in evolutionary separated groups of animals. Lack of ghrelin and MBOAT4 may be relevant to the way that these reptiles can live at a low energy demand for months or years. Their fat stores are used at a low level. The presence of many mutations in genes for aspects of mitochondrial function in these animals may also be involved in their reduced energy demand.
== Developments == A water-soluble prodrug, fospropofol, has been developed and tested with positive results. Fospropofol is rapidly broken down by the enzyme alkaline phosphatase to form propofol. Marketed as Lusedra, this formulation may not produce the pain at the injection site that often occurs with the conventional form of the drug. The U.S. Food and Drug Administration (FDA) approved the product in 2008. By incorporation of an azobenzene unit, a photoswitchable version of propofol (AP2) was developed in 2012 that allows for optical control of GABAA receptors with light. In 2013, a propofol binding site on mammalian GABAA receptors has been identified by photolabeling using a diazirine derivative. Additionally, it was shown that the hyaluronan polymer present in the synovia can be protected from free-radical depolymerization by propofol. Ciprofol is another derivative of propofol that is 4–6 times more potent than propofol. As of 2022 it is undergoing Phase III trials. Ciprofol appears to have a lower incidence of injection site pain and respiratory depression than propofol. Propofol has also been studied for treatment resistant depression.
Isoguanine and isocytosine, which have their amine and ketone inverted compared to standard guanine and cytosine. They are not used probably as tautomers are problematic for base pairing, but isoC and isoG can be amplified correctly with PCR even in the presence of the 4 canonical bases. Diaminopyrimidine and xanthine, which bind like 2-aminoadenine and thymine but with inverted structures. This pair is not used as xanthine is a deamination product.
=== Synthesis === The first reported manufacturing process for pregabalin was reported by Hoekstra and colleagues at Warner-Lambert in 1997, developed under the investigational name CI-1008. Initial preparations used an Evans chiral auxiliary to establish the (S)-stereocentre, but the selected manufacturing route employed racemic synthesis of 3-(aminomethyl)-5-methylhexanoic acid followed by diastereomeric salt formation with (S)-(+)-mandelic acid as the resolving agent. A more efficient enantioselective route was subsequently reported by Burk and colleagues, in which asymmetric hydrogenation of a salt of 3-cyano-5-methylhex-3-enoic acid using a rhodium/(R,R)-Me-DuPHOS catalyst gives the (S)-cyano intermediate in high enantiomeric excess (≥95% ee), followed by heterogeneous nickel-catalysed hydrogenation of the nitrile to afford pregabalin. A second-generation chemoenzymatic manufacturing process reported by Pfizer in 2008 uses a lipase-catalysed kinetic resolution of 2-carboxyethyl-3-cyano-5-methylhexanoic acid ethyl ester (CNDE) with Lipolase (a Thermomyces lanuginosus lipase supplied commercially by Novozymes), followed by thermal decarboxylation and nitrile reduction to give the final product. Following patent expiry, generic manufacturing routes have also been developed, including a process reported by Dr. Reddy's Laboratories in 2021 that combines continuous-flow nitroalkene synthesis with an asymmetric organocatalytic Michael addition as the stereodetermining step.
Sources: en.wikipedia.org
The solvent depends on peptide sequence and application. Water or aqueous buffer works for many hydrophilic peptides, while hydrophobic peptides may require a water-miscible organic solvent. The chosen solvent must be compatible with the assay or analytical instrument.
No. Some material may remain as insoluble particles, adsorb to surfaces, or degrade during handling. Recovery can be checked by analytical methods such as chromatography or mass spectrometry.
Aliquoting limits repeated freezing and thawing, which can cause aggregation or loss. Single-use portions also reduce contamination risk. Storage conditions depend on peptide stability.
It is the addition of a liquid to a dried peptide to produce a solution. The procedure changes the physical form, not the chemical identity of the peptide. It is a routine step in laboratory handling.